These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

69 related articles for article (PubMed ID: 19420948)

  • 41. Barriers to opioid substitution treatment access, entry and retention: a survey of opioid users, patients in treatment, and treating and non-treating physicians.
    Stöver H
    Eur Addict Res; 2011; 17(1):44-54. PubMed ID: 20975276
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Design, implementation and preliminary results of a type-2 hybrid cluster-randomized trial of integrating screening and treatment for major depressive disorder into specialty clinics providing opioid agonist therapies in Ukraine.
    Machavariani E; Bromberg DJ; Dumchev K; Dvoriak S; Zeziulin O; Morozova O; Esserman D; Pykalo I; Saichuk N; Ivasiy R; Haddad MS; Altice FL
    Contemp Clin Trials; 2023 Aug; 131():107248. PubMed ID: 37263492
    [TBL] [Abstract][Full Text] [Related]  

  • 43. Feasibility and Short-Term Effects of Low-Threshold Opioid Substitution Treatment during the COVID-19 Pandemic in Hamburg, Germany.
    Vorberg F; Reimer J; Verthein U
    Eur Addict Res; 2023; 29(1):44-51. PubMed ID: 36535264
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Piecing together stakeholder puzzles-puzzling about (opioid substitute treatment---OST) stakeholders and their pieces: a rambling point-of-view.
    Einstein S
    Subst Use Misuse; 2013 Aug; 48(11):1024-58. PubMed ID: 23952514
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Successful tuberculosis treatment in Ukraine.
    Holt E
    Lancet Infect Dis; 2023 May; 23(5):533. PubMed ID: 37086727
    [No Abstract]   [Full Text] [Related]  

  • 46. Resilience and perseverance under siege: providing cancer care during the invasion of Ukraine.
    Kizub D; Melnitchouk N; Beznosenko A; Shabat G; Semeniv S; Nogueira L; Watson PJ; Berg K; Trapido EJ; Espinel Z; Shultz JM
    Lancet Oncol; 2022 May; 23(5):579-583. PubMed ID: 35344704
    [No Abstract]   [Full Text] [Related]  

  • 47. The real-world impact of dosing of methadone and buprenorphine in retention on opioid agonist therapies in Ukraine.
    Farnum SO; Makarenko I; Madden L; Mazhnaya A; Marcus R; Prokhorova T; Bojko MJ; Rozanova J; Dvoriak S; Islam Z; Altice FL
    Addiction; 2021 Jan; 116(1):83-93. PubMed ID: 32428276
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Retention in Georgia opioid substitution therapy program and associated factors.
    Ruadze E; Todadze K
    Harm Reduct J; 2016 Dec; 13(1):35. PubMed ID: 27931232
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Geographic variability in HIV and injection drug use in Ukraine: implications for integration and expansion of drug treatment and HIV care.
    Zaller N; Mazhnaya A; Larney S; Islam Z; Shost A; Prokhorova T; Rybak N; Flanigan T
    Int J Drug Policy; 2015 Jan; 26(1):37-42. PubMed ID: 25304049
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Changes in quality of life (WHOQOL-BREF) and addiction severity index (ASI) among participants in opioid substitution treatment (OST) in low and middle income countries: an international systematic review.
    Feelemyer JP; Jarlais DCD; Arasteh K; Phillips BW; Hagan H
    Drug Alcohol Depend; 2014 Jan; 134():251-258. PubMed ID: 24200104
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Retention of participants in medication-assisted programs in low- and middle-income countries: an international systematic review.
    Feelemyer J; Des Jarlais D; Arasteh K; Abdul-Quader AS; Hagan H
    Addiction; 2014 Jan; 109(1):20-32. PubMed ID: 23859638
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Opiate substitution treatment and HIV transmission in people who inject drugs: systematic review and meta-analysis.
    MacArthur GJ; Minozzi S; Martin N; Vickerman P; Deren S; Bruneau J; Degenhardt L; Hickman M
    BMJ; 2012 Oct; 345():e5945. PubMed ID: 23038795
    [TBL] [Abstract][Full Text] [Related]  

  • 53. [Two-year follow-up of an opioid-user cohort treated with high-dose buprenorphine (Subutex)].
    Fhima A; Henrion R; Lowenstein W; Charpak Y
    Ann Med Interne (Paris); 2001 Apr; 152 Suppl 3():IS26-36. PubMed ID: 11435992
    [TBL] [Abstract][Full Text] [Related]  

  • 54. [Two years follow-up of a heroin users cohort treated with high dosage buprenorphine. Results of the SPESUB study (pharmacoepidemiologic follow-up of general practice Subutex)].
    Duburcq A; Charpak Y; Blin P; Madec L
    Rev Epidemiol Sante Publique; 2000 Aug; 48(4):363-73. PubMed ID: 11011303
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Adherence to HIV treatment among IDUs and the role of opioid substitution treatment (OST).
    Spire B; Lucas GM; Carrieri MP
    Int J Drug Policy; 2007 Aug; 18(4):262-70. PubMed ID: 17689374
    [TBL] [Abstract][Full Text] [Related]  

  • 56. The clinical efficacy and abuse potential of combination buprenorphine-naloxone in the treatment of opioid dependence.
    Mammen K; Bell J
    Expert Opin Pharmacother; 2009 Oct; 10(15):2537-44. PubMed ID: 19708849
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Feasibility of buprenorphine maintenance therapy programs in the Ukraine: first promising treatment outcomes.
    Schaub M; Subata E; Chtenguelov V; Weiler G; Uchtenhagen A
    Eur Addict Res; 2009; 15(3):157-62. PubMed ID: 19420948
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Feasibility of buprenorphine and methadone maintenance programmes among users of home made opioids in Ukraine.
    Schaub M; Chtenguelov V; Subata E; Weiler G; Uchtenhagen A
    Int J Drug Policy; 2010 May; 21(3):229-33. PubMed ID: 19926271
    [TBL] [Abstract][Full Text] [Related]  

  • 59.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

  • 60.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 4.